Full article view2018-07-17T08:45:50+00:00

Tomas Philipson Participates in AEI Panel on Pricing of Specialty Drugs

On Monday, September 12th, 2016 at AEI, health policy experts representing practitioners and industry discussed the issue of high drug prices.

On the panel, Precision Health Economics’ Tomas Philipson cast doubt on the claim that research and development determine pricing, arguing that in reality causality runs in the opposite direction. He noted potential flaws in value-based pricing and a one-size-fits-all-approach to global drug development and argued for more robust credit markets in health care.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK